23 September, 2024
Hynes Convention CenterPart of Biotech Week BostonAwards
Start-up of the Year
The Start-up of the Year award recognizes a burgeoning company that has blossomed into an industry leader through growth and innovation. Nominees can include companies that have raised substantial funding, innovated scientific advances, or created solutions to biology and business obstacles. The winning company will have smart leadership with a sustainable business model that poises it for long-term success in the years to come.
Finalists:
Ascidian Therapeutics
Avalyn Pharma
HiFiBiO Therapeutics
Kenai Therapeutics
Lucy Therapeutics, Inc.
Montai Therapeutics
Orbital Therapeutics
Rapport Therapeutics
DE&I Initiative
The DE&I Initiative award recognizes an organization or group that has advanced diversity, equity, and inclusion in the workplace by championing the perspectives and contributions of employees representing marginalized groups. To be considered, an organization must have a welcoming and inclusive culture, with diversity manifesting throughout its corporate structure, including in positions of leadership.
Finalists:
Agios Pharmaceuticals
DigitalDx Ventures
Entrada Therapeutics
LabCentral
Latinos in Bio, Inc
OUTbio, Inc.
Syner-G BioPharma Group, LLC
The CGT Circle
Biotech Innovation
The Biotech Innovation award recognises a company or organisation that has conceived a new or advancing biopharmaceutical product, manufacturing process or ground-breaking technology that yielded significant results.
Finalists:
Alkeus Pharmaceuticals, Inc.
Alltrna
Coya Therapeutics
Genialis
Micron Biomedical
Ori Biotech
PHIOGEN
Tome Biosciences
Deal of the Year
The Deal of the Year award recognizes the companies and individuals involved in forming a transformative business partnership, such as a major drug-licensing agreement or a successful merger/acquisition deal between companies. Deals that are considered for the award will be newsworthy and ambitious, and they will be projected to move the industry toward making positive impacts on the lives of patients.
Finalists:
Sanofi and Teva
Sanofi and Johnson & Johnson
Boston Institute of Biotechnology and 89bio
Quest Diagnostics and PathAI
PathAI and Roche Tissue Diagnostics (RTD)
Talent Acceleration
The Talent Acceleration award recognizes an organization that has shown exceptional aptitude for training scientists to develop the skills they need to thrive in the rapidly growing biopharmaceutical industry. To be considered, a company must offer a best-in-class training and development program with a proven track record of excellence that sets a new standard for the industry at large.
Finalists:
3PBiovian
BioBuilder
Biotechnology Business Institute
Rau Consulting, BioPharma Technical Consulting and University College Cork
SpringWorks Therapeutics
Sustainability Initiative
The Sustainability Initiative award recognizes the company that best embodies the spirit of ESG through a conscious effort to improve its environmental impact through policy, training, and innovation. To be considered, an organization must show commitment to the welfare of the planet by prioritizing its carbon-footprint reduction and by embedding environmentally conscious thinking into its company culture.
Finalists:
Cyclups Plantastiq
Diversified Biotech, Inc.
RoslinCT
Synterex
Clinical Advance of the Year
The Clinical Advance of the Year award recognizes an emerging drug that has passed through clinical trials and is expected to have a ground-breaking impact on healthcare in the years to come. The winner of this award will be an exciting new drug that not only stands to improve patient outcomes, but also holds promise for changing the standard of care for a given indication.
Finalists:
Allogene
Alzheon
Delix Therapeutics
Immunic Therapeutics
Nested Therapeutics
Servier Pharmaceuticals
Lifetime Achievement Award
The Lifetime Achievement award recognizes an exceptional individual who has served the industry beyond the call of duty throughout a distinguished career. To be considered for this prestigious international award, a nominee will have committed decades to enhancing the lives of others through drug development, patient care, innovation, training, and/or meeting other critical needs within the biotechnology or pharmaceutical arena.
Finalists:
David Kahn VP Biopharmaceutical Development, MacroGenics, Inc. since Sep 2018 (recently retired)
John Carpenter Professor Emeritus at University of Colorado Anschutz Medical Campus
John Curling John Curling Consulting AB
Laura Johnson Verismo Therapeutics
Liang Schweizer HiFiBiO Therapeutics
Mary Anne Heino Lantheus
Prabu Nambiar Syner-G BioPharma Group, LLC
Tim Charlebois Retired (Pfizer)
Boston Highlight
The Boston Highlight award recognizes a standout life-sciences organization or person based in the Boston area that has made a significant contribution to the biopharmaceutical industry over the past year. Nominees will have propelled scientific innovation, made advances in novel technologies, or contributed significantly to the health and welfare of patients. This award will consider a breadth of candidates and can recognize a leader from industry, academia, medicine, digital health, or healthcare.
Finalists:
Aurion Biotech
Beam Therapeutics
Boston Institute of Biotechnology, LLC
Delphia Therapeutics
Dewpoint Therapeutics
FogPharma
LaVoieHealthScience
Rapport Therapeutics
Transformational Therapy
The Transformational Therapy award recognizes innovation in the discovery, development, delivery, and/or market accessibility of an advanced-therapy drug product that is designed to treat rare diseases with currently unmet medical needs. This award celebrates the industry’s growth in the advanced-therapy sector and recognizes a company or individual spearheading efforts to bring much-needed therapies to patients.
Finalists:
Alexion, AstraZeneca Rare Disease
Elicio Therapeutics
Indaptus Therapeutics
Kudo Biotechnology
Nested Therapeutics
ONCURNA
Sarepta Therapeutics
Verismo Therapeutics